Pridopidine can be made available to patients who have completed the MermaiHD open-label phase. The practicalities around this expanded access program has been outsourced by NeuroSearch to a company named Idis.
Idis can be contacted via phone, fax or e-mail on the following numbers/addresses:

Telephone

UK:	+44 (0) 1932 824 100
France:	+33 (0) 1 55 27 39 32
Germany:	+49 (0) 89 9700 7409
Italy:	+39 (0) 02 7254 6841
Spain:	+34 (0) 93 344 3224
Other:	+44 (0) 1932 824 123

Fax

UK:	+44 (0) 1932 824 300
France:	+33 (0) 1 55 27 37 00
Germany:	+49 (0) 89 9700 7200
Italy:	+39 (0) 02 7254 6430
Spain:	+34 (0) 93 344 3216
Other:	+44 (0) 1932 824 323

After you've contacted Idis with a request for pridopidine you will receive an information package including:

• a description of the compassionate use program, which includes inclusion and exclusion criteria for treatment and procedures
• an access form which must be filled in and returned to Idis before any drug can be supplied
• summary of data and guidance for the treating physician (which is the same information as given in section 7 of the Investigator's Brochure)
• a template for informed consent (for you to translate into local language, if appropriate, and adapted to your local regulations)
• an adverse event form

Different EU countries have different regulatory procedures for compassionate use, and Idis will be able to advise you in the process for obtaining the necessary approvals. Once the approvals are in place, and the signed access form has been received by Idis, drug will be shipped from Idis to your hospital pharmacy for dispensing to the patient.